News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|January 7, 2025

When to Consider Systemic Treatment for Prurigo Nodularis Patients

Author(s)TJ Chao, MPAS, PA-C

TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.

Episodes in this series

EP. 1 Prurigo Nodularis Burden of Disease

EP. 1 Prurigo Nodularis Burden of Disease

EP. 2 Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

EP. 2 Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

EP. 3 New Systemic Treatments for Prurigo Nodularis

EP. 3 New Systemic Treatments for Prurigo Nodularis

EP. 4 Talking to Patients About Itch Management

EP. 4 Talking to Patients About Itch Management

EP. 5 Provider and Patient Considerations for Prurigo Nodularis Treatment

EP. 5 Provider and Patient Considerations for Prurigo Nodularis Treatment

EP. 6 The Burden of Prurigo Nodularis

EP. 7 Considerations for Setting Treatment Goals in Prurigo Nodularis

EP. 7 Considerations for Setting Treatment Goals in Prurigo Nodularis

EP. 8 New Systemic Treatment Options for Prurigo Nodularis

EP. 8 New Systemic Treatment Options for Prurigo Nodularis

EP. 9 A Rapidly Changing Landscape in Prurigo Nodularis Signals New Directions and Opportunities for Treatment

EP. 10 When to Consider Systemic Treatment for Prurigo Nodularis Patients

EP. 10 When to Consider Systemic Treatment for Prurigo Nodularis Patients

EP. 11 Educating Patients on Systemic Prurigo Nodularis Treatment and Adherence

EP. 11 Educating Patients on Systemic Prurigo Nodularis Treatment and Adherence

EP. 12 Key Takeaways for Prurigo Nodularis Treatment

EP. 12 Key Takeaways for Prurigo Nodularis Treatment

Video content above is prompted by the following:

For which type of patient would you consider systemic treatments for prurigo nodularis patients?

What patient-specific factors do you consider when starting treatment?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN

ByMarie Bosslett, Assistant Editor

December 4th 2025

Clinical Pearls for Management of Pediatric Atopic Dermatitis With Topicals

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Therapy Gaps in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 21st 2025

Counseling Caregivers in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Escalating to Systemic Therapies in Pediatric Atopic Dermatitis

ByPeter Lio, MD,Jeff Yu, MD, MS

November 14th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2

Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases

FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756